Combining the KRAS<sup>G12C</sup> inhibitor adagrasib with anti-PD-1 immunotherapy improves overall survival and prevents recurrence in preclinical models of brain metastasis.

Neurooncol Adv · 2026 · PMC13242296 · PMID 42254833

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Despite a reduction in tumor volumes in mice receiving anti-PD-1, in this model, it did not reach statistical significance compared to the vehicle group.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Combining the KRAS&lt;sup&gt;G12C&lt;/sup&gt; inhibitor adagrasib with anti-PD-1 immunotherapy improves overall survival and prevents recurrence in preclinical models of brain metastasis.

The sentences

Combining the KRAS<sup>G12C</sup> inhibitor adagrasib with anti-PD-1 immunotherapy improves overall survival and prevents recurrence in preclinical models of brain metastasis.